Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom

The use of adjuvant is of fundamental importance in vaccines formulations and antisera production. Currently selection and use of adjuvant systems in snake antivenom preparation has become a major issue in terms of animal welfare as well as economics. In order to minimize disadvantages associated wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2009-02, Vol.27 (7), p.1067
Hauptverfasser: Waghmare, Arun, Deopurkar, R L, Salvi, Nitin, Khadilkar, Milind, Kalolikar, Milind, Gade, S K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 7
container_start_page 1067
container_title Vaccine
container_volume 27
creator Waghmare, Arun
Deopurkar, R L
Salvi, Nitin
Khadilkar, Milind
Kalolikar, Milind
Gade, S K
description The use of adjuvant is of fundamental importance in vaccines formulations and antisera production. Currently selection and use of adjuvant systems in snake antivenom preparation has become a major issue in terms of animal welfare as well as economics. In order to minimize disadvantages associated with traditionally used Freund's adjuvant (FA) in equines and to produce potent polyvalent antivenom against four Indian snake venoms in minimum possible period, a comparison was made between various commercially available non-emulsion/emulsion based adjuvants like IMS 3012, ISA 206 and ISA 35 with Incomplete Freund's adjuvant (IFA) for their immunopotentiation capacity and safety in donor animals. The present study was conducted in 33 new horses, randomly divided into four groups and hyperimmunized using crude mixture of snake venoms, viz.; Cobra venom (CV), Russell's viper venom (RV), Krait venom (KV) and Saw-scaled viper (EV) along with four above mentioned adjuvants through subcutaneous (s.c.) route at intervals of two weeks. Periodic standard safety assessments were done. Immunopotentiation ability of each adjuvant group in terms of percent responders were estimated at 14th, 21st, 30th and 43rd week. The neutralization activity (ED(50)) of pooled sera samples by 43(rd) week, obtained with IMS 3012 group for CV, RV, KV and EV venoms were 0.133, 0.143, 0.070 and 0.270 mg venom/ml of serum respectively. The antivenom potency with IMS 3012 and overall responding horses (100%) even against weak immunogen like CV was significantly higher (p
doi_str_mv 10.1016/j.vaccine.2008.11.103
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_19100805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19100805</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-36c26bc24df127921e86609d5a1935c3c700e1449eedfd572b6f75c8bae5e3483</originalsourceid><addsrcrecordid>eNo9UMtOAjEU7UIjiH6CpjshEexjOjBLQkBJQBewcEc67R0pzrTjdAaDn-rX2IC6ujf3nJzHReiGkgElNH7YDfZSKWNhwAgZDSgNZ36G2oTFUT-i5LWFLr3fEUIEp8kFatGEBiIRbfQ9cUUpK-OdxS7DS2draY0GLPWu2Utb-3s8X64wJ5Th7rO0LrBro3LoBWA1xozEWFp93LnA3WnR5N4EtVR60D0sc2ff8Kept9hYFcxyqAHPKmisvvP_NjhzFd4eSqhMUTTWfMnanCLBRxOaedwEuSOrrJxu1B9cuvywlzkECW_lewhua7MH64ordJ7J3MP17-yg9Wy6njz1Fy-P88l40S9FJPo8VixOFYt0RtkwYRRGcUwSLSRNuFBcDQkBGkUJgM60GLI0zoZCjVIJAng04h10e5Itm7QAvSlDA1kdNn8_5j8v84FO</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Waghmare, Arun ; Deopurkar, R L ; Salvi, Nitin ; Khadilkar, Milind ; Kalolikar, Milind ; Gade, S K</creator><creatorcontrib>Waghmare, Arun ; Deopurkar, R L ; Salvi, Nitin ; Khadilkar, Milind ; Kalolikar, Milind ; Gade, S K</creatorcontrib><description>The use of adjuvant is of fundamental importance in vaccines formulations and antisera production. Currently selection and use of adjuvant systems in snake antivenom preparation has become a major issue in terms of animal welfare as well as economics. In order to minimize disadvantages associated with traditionally used Freund's adjuvant (FA) in equines and to produce potent polyvalent antivenom against four Indian snake venoms in minimum possible period, a comparison was made between various commercially available non-emulsion/emulsion based adjuvants like IMS 3012, ISA 206 and ISA 35 with Incomplete Freund's adjuvant (IFA) for their immunopotentiation capacity and safety in donor animals. The present study was conducted in 33 new horses, randomly divided into four groups and hyperimmunized using crude mixture of snake venoms, viz.; Cobra venom (CV), Russell's viper venom (RV), Krait venom (KV) and Saw-scaled viper (EV) along with four above mentioned adjuvants through subcutaneous (s.c.) route at intervals of two weeks. Periodic standard safety assessments were done. Immunopotentiation ability of each adjuvant group in terms of percent responders were estimated at 14th, 21st, 30th and 43rd week. The neutralization activity (ED(50)) of pooled sera samples by 43(rd) week, obtained with IMS 3012 group for CV, RV, KV and EV venoms were 0.133, 0.143, 0.070 and 0.270 mg venom/ml of serum respectively. The antivenom potency with IMS 3012 and overall responding horses (100%) even against weak immunogen like CV was significantly higher (p&lt;0.05) than other three adjuvants studied. The horses of IMS 3012 group showed minimum local reactions at injection site, while horses from other three groups exhibited moderate (++) reactions; 66.7% in ISA 206, 12.5% in ISA 35 and 14.3% in IFA respectively, however these were transient and reabsorbed or healed subsequently. Finally, we conclude that, nanoparticle adjuvant IMS 3012 could be a possible alternative to the emulsion adjuvants for primary phase of immunization in antivenom preparation considering its better immunopotentiation capacity and safety in donor animals.</description><identifier>ISSN: 0264-410X</identifier><identifier>DOI: 10.1016/j.vaccine.2008.11.103</identifier><identifier>PMID: 19100805</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Adjuvants, Immunologic - administration &amp; dosage ; Adjuvants, Immunologic - adverse effects ; Adjuvants, Immunologic - pharmacology ; Animals ; Antivenins - blood ; Emulsions - administration &amp; dosage ; Emulsions - adverse effects ; Emulsions - pharmacology ; Female ; Freund's Adjuvant - administration &amp; dosage ; Freund's Adjuvant - adverse effects ; Freund's Adjuvant - pharmacology ; Horses ; Immunization, Secondary - methods ; Injections, Subcutaneous ; Lipids - administration &amp; dosage ; Lipids - adverse effects ; Lipids - pharmacology ; Longitudinal Studies ; Male ; Nanoparticles - administration &amp; dosage ; Nanoparticles - adverse effects ; Nanoparticles - chemistry ; Neutralization Tests ; Snake Venoms - immunology</subject><ispartof>Vaccine, 2009-02, Vol.27 (7), p.1067</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19100805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Waghmare, Arun</creatorcontrib><creatorcontrib>Deopurkar, R L</creatorcontrib><creatorcontrib>Salvi, Nitin</creatorcontrib><creatorcontrib>Khadilkar, Milind</creatorcontrib><creatorcontrib>Kalolikar, Milind</creatorcontrib><creatorcontrib>Gade, S K</creatorcontrib><title>Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>The use of adjuvant is of fundamental importance in vaccines formulations and antisera production. Currently selection and use of adjuvant systems in snake antivenom preparation has become a major issue in terms of animal welfare as well as economics. In order to minimize disadvantages associated with traditionally used Freund's adjuvant (FA) in equines and to produce potent polyvalent antivenom against four Indian snake venoms in minimum possible period, a comparison was made between various commercially available non-emulsion/emulsion based adjuvants like IMS 3012, ISA 206 and ISA 35 with Incomplete Freund's adjuvant (IFA) for their immunopotentiation capacity and safety in donor animals. The present study was conducted in 33 new horses, randomly divided into four groups and hyperimmunized using crude mixture of snake venoms, viz.; Cobra venom (CV), Russell's viper venom (RV), Krait venom (KV) and Saw-scaled viper (EV) along with four above mentioned adjuvants through subcutaneous (s.c.) route at intervals of two weeks. Periodic standard safety assessments were done. Immunopotentiation ability of each adjuvant group in terms of percent responders were estimated at 14th, 21st, 30th and 43rd week. The neutralization activity (ED(50)) of pooled sera samples by 43(rd) week, obtained with IMS 3012 group for CV, RV, KV and EV venoms were 0.133, 0.143, 0.070 and 0.270 mg venom/ml of serum respectively. The antivenom potency with IMS 3012 and overall responding horses (100%) even against weak immunogen like CV was significantly higher (p&lt;0.05) than other three adjuvants studied. The horses of IMS 3012 group showed minimum local reactions at injection site, while horses from other three groups exhibited moderate (++) reactions; 66.7% in ISA 206, 12.5% in ISA 35 and 14.3% in IFA respectively, however these were transient and reabsorbed or healed subsequently. Finally, we conclude that, nanoparticle adjuvant IMS 3012 could be a possible alternative to the emulsion adjuvants for primary phase of immunization in antivenom preparation considering its better immunopotentiation capacity and safety in donor animals.</description><subject>Adjuvants, Immunologic - administration &amp; dosage</subject><subject>Adjuvants, Immunologic - adverse effects</subject><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Animals</subject><subject>Antivenins - blood</subject><subject>Emulsions - administration &amp; dosage</subject><subject>Emulsions - adverse effects</subject><subject>Emulsions - pharmacology</subject><subject>Female</subject><subject>Freund's Adjuvant - administration &amp; dosage</subject><subject>Freund's Adjuvant - adverse effects</subject><subject>Freund's Adjuvant - pharmacology</subject><subject>Horses</subject><subject>Immunization, Secondary - methods</subject><subject>Injections, Subcutaneous</subject><subject>Lipids - administration &amp; dosage</subject><subject>Lipids - adverse effects</subject><subject>Lipids - pharmacology</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Nanoparticles - administration &amp; dosage</subject><subject>Nanoparticles - adverse effects</subject><subject>Nanoparticles - chemistry</subject><subject>Neutralization Tests</subject><subject>Snake Venoms - immunology</subject><issn>0264-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UMtOAjEU7UIjiH6CpjshEexjOjBLQkBJQBewcEc67R0pzrTjdAaDn-rX2IC6ujf3nJzHReiGkgElNH7YDfZSKWNhwAgZDSgNZ36G2oTFUT-i5LWFLr3fEUIEp8kFatGEBiIRbfQ9cUUpK-OdxS7DS2draY0GLPWu2Utb-3s8X64wJ5Th7rO0LrBro3LoBWA1xozEWFp93LnA3WnR5N4EtVR60D0sc2ff8Kept9hYFcxyqAHPKmisvvP_NjhzFd4eSqhMUTTWfMnanCLBRxOaedwEuSOrrJxu1B9cuvywlzkECW_lewhua7MH64ordJ7J3MP17-yg9Wy6njz1Fy-P88l40S9FJPo8VixOFYt0RtkwYRRGcUwSLSRNuFBcDQkBGkUJgM60GLI0zoZCjVIJAng04h10e5Itm7QAvSlDA1kdNn8_5j8v84FO</recordid><startdate>20090211</startdate><enddate>20090211</enddate><creator>Waghmare, Arun</creator><creator>Deopurkar, R L</creator><creator>Salvi, Nitin</creator><creator>Khadilkar, Milind</creator><creator>Kalolikar, Milind</creator><creator>Gade, S K</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20090211</creationdate><title>Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom</title><author>Waghmare, Arun ; Deopurkar, R L ; Salvi, Nitin ; Khadilkar, Milind ; Kalolikar, Milind ; Gade, S K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-36c26bc24df127921e86609d5a1935c3c700e1449eedfd572b6f75c8bae5e3483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adjuvants, Immunologic - administration &amp; dosage</topic><topic>Adjuvants, Immunologic - adverse effects</topic><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Animals</topic><topic>Antivenins - blood</topic><topic>Emulsions - administration &amp; dosage</topic><topic>Emulsions - adverse effects</topic><topic>Emulsions - pharmacology</topic><topic>Female</topic><topic>Freund's Adjuvant - administration &amp; dosage</topic><topic>Freund's Adjuvant - adverse effects</topic><topic>Freund's Adjuvant - pharmacology</topic><topic>Horses</topic><topic>Immunization, Secondary - methods</topic><topic>Injections, Subcutaneous</topic><topic>Lipids - administration &amp; dosage</topic><topic>Lipids - adverse effects</topic><topic>Lipids - pharmacology</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Nanoparticles - administration &amp; dosage</topic><topic>Nanoparticles - adverse effects</topic><topic>Nanoparticles - chemistry</topic><topic>Neutralization Tests</topic><topic>Snake Venoms - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Waghmare, Arun</creatorcontrib><creatorcontrib>Deopurkar, R L</creatorcontrib><creatorcontrib>Salvi, Nitin</creatorcontrib><creatorcontrib>Khadilkar, Milind</creatorcontrib><creatorcontrib>Kalolikar, Milind</creatorcontrib><creatorcontrib>Gade, S K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Waghmare, Arun</au><au>Deopurkar, R L</au><au>Salvi, Nitin</au><au>Khadilkar, Milind</au><au>Kalolikar, Milind</au><au>Gade, S K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2009-02-11</date><risdate>2009</risdate><volume>27</volume><issue>7</issue><spage>1067</spage><pages>1067-</pages><issn>0264-410X</issn><abstract>The use of adjuvant is of fundamental importance in vaccines formulations and antisera production. Currently selection and use of adjuvant systems in snake antivenom preparation has become a major issue in terms of animal welfare as well as economics. In order to minimize disadvantages associated with traditionally used Freund's adjuvant (FA) in equines and to produce potent polyvalent antivenom against four Indian snake venoms in minimum possible period, a comparison was made between various commercially available non-emulsion/emulsion based adjuvants like IMS 3012, ISA 206 and ISA 35 with Incomplete Freund's adjuvant (IFA) for their immunopotentiation capacity and safety in donor animals. The present study was conducted in 33 new horses, randomly divided into four groups and hyperimmunized using crude mixture of snake venoms, viz.; Cobra venom (CV), Russell's viper venom (RV), Krait venom (KV) and Saw-scaled viper (EV) along with four above mentioned adjuvants through subcutaneous (s.c.) route at intervals of two weeks. Periodic standard safety assessments were done. Immunopotentiation ability of each adjuvant group in terms of percent responders were estimated at 14th, 21st, 30th and 43rd week. The neutralization activity (ED(50)) of pooled sera samples by 43(rd) week, obtained with IMS 3012 group for CV, RV, KV and EV venoms were 0.133, 0.143, 0.070 and 0.270 mg venom/ml of serum respectively. The antivenom potency with IMS 3012 and overall responding horses (100%) even against weak immunogen like CV was significantly higher (p&lt;0.05) than other three adjuvants studied. The horses of IMS 3012 group showed minimum local reactions at injection site, while horses from other three groups exhibited moderate (++) reactions; 66.7% in ISA 206, 12.5% in ISA 35 and 14.3% in IFA respectively, however these were transient and reabsorbed or healed subsequently. Finally, we conclude that, nanoparticle adjuvant IMS 3012 could be a possible alternative to the emulsion adjuvants for primary phase of immunization in antivenom preparation considering its better immunopotentiation capacity and safety in donor animals.</abstract><cop>Netherlands</cop><pmid>19100805</pmid><doi>10.1016/j.vaccine.2008.11.103</doi></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2009-02, Vol.27 (7), p.1067
issn 0264-410X
language eng
recordid cdi_pubmed_primary_19100805
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adjuvants, Immunologic - administration & dosage
Adjuvants, Immunologic - adverse effects
Adjuvants, Immunologic - pharmacology
Animals
Antivenins - blood
Emulsions - administration & dosage
Emulsions - adverse effects
Emulsions - pharmacology
Female
Freund's Adjuvant - administration & dosage
Freund's Adjuvant - adverse effects
Freund's Adjuvant - pharmacology
Horses
Immunization, Secondary - methods
Injections, Subcutaneous
Lipids - administration & dosage
Lipids - adverse effects
Lipids - pharmacology
Longitudinal Studies
Male
Nanoparticles - administration & dosage
Nanoparticles - adverse effects
Nanoparticles - chemistry
Neutralization Tests
Snake Venoms - immunology
title Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A17%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Montanide%20adjuvants,%20IMS%203012%20(Nanoparticle),%20ISA%20206%20and%20ISA%2035%20(Emulsion%20based)%20along%20with%20incomplete%20Freund's%20adjuvant%20for%20hyperimmunization%20of%20equines%20used%20for%20production%20of%20polyvalent%20snake%20antivenom&rft.jtitle=Vaccine&rft.au=Waghmare,%20Arun&rft.date=2009-02-11&rft.volume=27&rft.issue=7&rft.spage=1067&rft.pages=1067-&rft.issn=0264-410X&rft_id=info:doi/10.1016/j.vaccine.2008.11.103&rft_dat=%3Cpubmed%3E19100805%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19100805&rfr_iscdi=true